|
1
|
ATP-binding cassette transporter A1 locus is not a major determinant of HDL-C levels in a population at high risk for coronary heart disease.
|
Atherosclerosis
|
2003
|
1.58
|
|
2
|
ATP binding cassette transporter G5 and G8 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin.
|
J Lipid Res
|
2004
|
1.28
|
|
3
|
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans.
|
Arterioscler Thromb Vasc Biol
|
2006
|
1.13
|
|
4
|
Common genetic variation in multiple metabolic pathways influences susceptibility to low HDL-cholesterol and coronary heart disease.
|
J Lipid Res
|
2010
|
1.03
|
|
5
|
Apolipoprotein A-I, B-100, and B-48 metabolism in subjects with chronic kidney disease, obesity, and the metabolic syndrome.
|
Metabolism
|
2004
|
1.01
|
|
6
|
CYP3A4 genotypes and plasma lipoprotein levels before and after treatment with atorvastatin in primary hypercholesterolemia.
|
Am J Cardiol
|
2004
|
0.97
|
|
7
|
Polymorphisms in the multidrug resistance-1 (MDR1) gene influence the response to atorvastatin treatment in a gender-specific manner.
|
Am J Cardiol
|
2004
|
0.95
|
|
8
|
A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin.
|
Atherosclerosis
|
2005
|
0.95
|
|
9
|
Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin.
|
Atherosclerosis
|
2004
|
0.93
|
|
10
|
Pharmacogenetics of HMG-CoA reductase inhibitors: exploring the potential for genotype-based individualization of coronary heart disease management.
|
Atherosclerosis
|
2004
|
0.91
|
|
11
|
The L162V polymorphism at the peroxisome proliferator activated receptor alpha locus modulates the risk of cardiovascular events associated with insulin resistance and diabetes mellitus: the Veterans Affairs HDL Intervention Trial (VA-HIT).
|
Atherosclerosis
|
2005
|
0.88
|
|
12
|
Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism.
|
J Lipid Res
|
2007
|
0.86
|
|
13
|
Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism.
|
Atherosclerosis
|
2005
|
0.83
|
|
14
|
Codon 54 polymorphism of the fatty acid binding protein (FABP) 2 gene is associated with increased cardiovascular risk in the dyslipidemic diabetic participants of the Veterans Affairs HDL intervention trial (VA-HIT).
|
Atherosclerosis
|
2006
|
0.81
|
|
15
|
In vivo metabolism of apolipoprotein E within the HDL subpopulations LpE, LpE:A-I, LpE:A-II and LpE:A-I:A-II.
|
Atherosclerosis
|
2002
|
0.79
|
|
16
|
Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism.
|
J Lipid Res
|
2012
|
0.79
|